Pro-Dex (NASDAQ:PDEX) Earns Hold Rating from Analysts at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Pro-Dex (NASDAQ:PDEXGet Rating) in a research report issued on Wednesday. The brokerage set a “hold” rating on the medical instruments supplier’s stock.

Separately, Ascendiant Capital Markets reduced their price objective on shares of Pro-Dex to $30.00 and set a “na” rating on the stock in a research note on Monday, May 16th.

Pro-Dex stock opened at $15.73 on Wednesday. The company’s 50 day simple moving average is $15.38 and its 200 day simple moving average is $18.72. Pro-Dex has a fifty-two week low of $12.40 and a fifty-two week high of $32.62. The firm has a market capitalization of $56.93 million, a price-to-earnings ratio of 18.08 and a beta of 1.11. The company has a debt-to-equity ratio of 0.47, a current ratio of 3.64 and a quick ratio of 2.10.

Pro-Dex (NASDAQ:PDEXGet Rating) last released its quarterly earnings data on Thursday, May 5th. The medical instruments supplier reported $0.12 earnings per share for the quarter. Pro-Dex had a net margin of 8.50% and a return on equity of 15.41%. The business had revenue of $9.27 million for the quarter.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. State Street Corp lifted its stake in Pro-Dex by 5.8% in the first quarter. State Street Corp now owns 11,923 shares of the medical instruments supplier’s stock valued at $197,000 after buying an additional 650 shares in the last quarter. LSV Asset Management lifted its stake in Pro-Dex by 13.9% in the first quarter. LSV Asset Management now owns 35,581 shares of the medical instruments supplier’s stock valued at $588,000 after buying an additional 4,346 shares in the last quarter. BlackRock Inc. lifted its stake in Pro-Dex by 10.7% in the third quarter. BlackRock Inc. now owns 49,114 shares of the medical instruments supplier’s stock valued at $1,261,000 after buying an additional 4,752 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in Pro-Dex by 59.2% in the first quarter. JPMorgan Chase & Co. now owns 20,863 shares of the medical instruments supplier’s stock valued at $345,000 after buying an additional 7,762 shares in the last quarter. 16.73% of the stock is currently owned by hedge funds and other institutional investors.

Pro-Dex Company Profile (Get Rating)

Pro-Dex, Inc designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.

Featured Articles

Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.